Each of the three TAAs, ASB-9 (36/87 (41.3%), P = .0112), SERAC1 (41/87 (47.1%), P = .0009), and RELT (46/87 (52.9%), P = .0001) elicited significantly higher frequency of AAbs in breast carcinoma patients compared to healthy controls. Here, SERAC1 is linked to breast carcinoma.